What are the common side effects of candesartan?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 10, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Common Side Effects of Candesartan

The most common side effects of candesartan are hypotension, hyperkalemia, worsening renal function, headache, dizziness, and upper respiratory tract infections, with the overall tolerability profile similar to placebo. 1, 2

Cardiovascular and Hemodynamic Effects

  • Hypotension is a key side effect, particularly in volume-depleted patients or those on concurrent diuretics, requiring blood pressure monitoring within 1-2 weeks of initiation 1, 2

  • Symptomatic hypotension occurs most frequently in patients with prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting 2

  • In heart failure patients, candesartan may cause excessive hypotension leading to oliguria, azotemia, and rarely acute renal failure 2

Electrolyte Disturbances

  • Hyperkalemia is as likely with candesartan as with ACE inhibitors due to suppression of aldosterone, reducing potassium excretion in the distal tubule 1

  • In clinical trials, hyperkalemia (serum potassium >5.7 mEq/L) occurred in 0.4% of patients on candesartan versus 1.0% on placebo 2

  • Risk increases substantially in patients with chronic kidney disease, diabetes mellitus, heart failure, or those taking potassium supplements, potassium-sparing diuretics, or NSAIDs 1, 2

  • Monitor serum potassium and renal function at baseline and within 1-2 weeks after initiation or dose changes 1

Renal Effects

  • Worsening renal function including acute renal failure can occur, particularly in patients whose renal function depends on the renin-angiotensin system 2

  • Patients at highest risk include those with renal artery stenosis, chronic kidney disease, severe heart failure, or volume depletion 2

  • Renal function should be monitored periodically, with consideration to withhold or discontinue therapy if clinically significant decline occurs 2

Common Non-Serious Adverse Events

  • Headache is the most frequently reported adverse event across clinical trials 3, 4, 5

  • Dizziness, nausea, diarrhea, back pain, and upper respiratory tract infections occur at rates similar to placebo 3, 4, 5

  • Transient elevations in liver transaminases may occur but are generally mild 3

  • Cough incidence is similar to placebo, making candesartan an excellent alternative for patients intolerant to ACE inhibitors due to cough 3, 4, 5

Important Clinical Distinctions

  • All adverse events are usually mild to moderate in severity and not dose-related 4, 5

  • The tolerability profile does not differ significantly from placebo in pooled analyses 4, 5

  • Long-term tolerability is not different from short-term trials, with no increase in adverse events over time 4

  • Tolerability does not differ by age or gender 4, 6

Rare but Serious Reactions

  • Angioedema is much less frequent with candesartan than ACE inhibitors, though rare cases have occurred in patients who previously developed angioedema to ACE inhibitors 1

  • Fetal toxicity including oligohydramnios, hypotension, renal failure, and death can occur with second and third trimester exposure; discontinue immediately when pregnancy is detected 2

Monitoring Requirements

  • Check blood pressure (including postural changes), renal function, and potassium within 1-2 weeks after initiation and after dose adjustments 1

  • Patients with systolic blood pressure <80 mmHg, low serum sodium, diabetes mellitus, or impaired renal function require particularly close surveillance 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Candesartan cilexetil: an angiotensin II-receptor blocker.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2000

Research

Candesartan.

Cardiovascular drug reviews, 2004

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.